Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (6511)	1/19/2001 9:55:48 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

BJ, This will be enough to set up Canada and plenty more. Canadian approval is not far away. I see it as April latest. We already have several thousand waiting customers. I know more than 20 including myself. Don't laugh, at $540 a year, that's $10,000 a year in sales right there. (The 20 people times $45 times 12) A good thing about Canada, is that while it's a small market, we keep all the profit. In essence we pay the 20% royalty to ourselves. Looks like a less boring year ahead. This is the end of waiting for somebody else to move ahead on plans. I hope those plans are good. Last placement was at $4.05, these will be at no less than $6.50. Some interesting dynamics now come into play. We dilute - but most keep the shareprice above $6.50. The only way to do that is to perform. Is that confidence I smell? Rebecca please take this the right way. You the man! Wolf

To: DaveAu who wrote (6511)	1/19/2001 10:11:52 PM
From: john.d	Read Replies (4) \| Respond to of 14101

To all, Here are my initial thoughts. Before I start I will say this, if there's anything I've learned, it’s that nothing should surprise me anymore from Ms. Keeler. Here goes: 1)Creates an incentive for Dimethaid to raise their share price and minimize dilution. 2)Provides flexibility in negotiations with marketing partners. No one can hold a gun to Rebecca’s head now; something that J&J may have been trying to do? 3)Allows the company to hire the necessary staff and move forward aggressively with the business plan to develop more products around the delivery platform. The patent on the transdermal carrier expires in 2006, so she can’t sit around waiting for marketing partner payments forever. 4)With WF10 AIDS phase III trials finishing up in June, this provides sufficient flexibility for Rebecca to direct funds to OXO to prepare regulatory submissions for prime world markets upon completion of the phase III trials and subsequent analysis. A regulatory submission is likely a costly and lengthy process and we know Oxo is short of cash. This funding may position them to make submissions in a timely fashion. I think we can expect to see Dimethaid increase their equity position once the phase III trial results are announced. Very positive in this respect. 5)Also provides flexibility for Dimethaid to direct funds to Oxo for other trials now underway (i.e.: prostate cancer, etc.) 6)Agua has to believe that the stock has potential to exceed $25 to set this is a maximum purchase price. 7)A $50 million financing is significant, we are moving into the bid time! 8)This may signal that Rebecca does not expect significant up front payments from the Euro Partner and/or J&J any time soon. On the same token, this may not be the case since this deal is very flexible. If she gets what she wants from the marketing partners she may not need to use a large portion of the funds 9)Could this suggest that we will not see a NASDAQ listing this year? 10)Could this signal that FDA approval is further away than we think? Doubt it, but makes me wonder. Overall, I'd say it's a pretty interesting and positive deal. John

To: DaveAu who wrote (6511)	1/20/2001 9:06:51 AM
From: the Chief	Read Replies (1) \| Respond to of 14101

Chief, what's your take on this financing. Acqua seems to do a lot of these deals with bio tech companies. Any concern that Acqua will be shorting the shares ? I know there is a 120 day holding period but that doesn't prevent them from shorting in another account. I really like the deal, I think Rebecca has done a superb job, and I offer an apology to Rebecca for misunderstanding her objectives. This puts DMX in th eposition to continue to demand higher margins and royalties for Pennsaid without worrying about being intimidated by the large pharmas. Acqua would likely beome an "also ran" in the financing of bio tech companies if they were to be found shorting and "manipulating" the stock of one of their clients. Proving a large short that keeps a stock down is relatively easy and is traceable so I don't think it would be in their best interest...to say the least. 3 month hold is not a big deal actally, what will be interesting is to observe the stock 3 months after the first trenche of financing is completed...will they sell, or will they hold. I will be adding to my LT account Monday the Chief